Document is current
Any future updates will be listed below
-
Authors
Mimura, Chihiro
Takamiya, Rei
Fujimoto, Shodai
Fukui, Takafumi
Yatani, Atsuhiko
Yamada, Jun
Takayasu, Mizuki
Takata, Naoya
Sato, Hiroki
Fukuda, Kiyoko
Furukawa, Koichi
Hazama, Daisuke
Katsurada, Naoko
Yamamoto, Masatsugu
Matsumoto, Shingo
Goto, Koichi
Tachihara, Motoko
- License Information
-
More Information
Article History
Received: 18 January 2024
Accepted: 11 April 2024
First Online: 17 April 2024
Declarations
:
: Informed consent was obtained from all the enrolled patients. This study was approved by the Kobe University Ethics Committee (230046) on July 19, 2023. This study was conducted in accordance with the principles of the Declaration of Helsinki. This was registered with the University Medical Hospital Information Network in Japan (UMINCTR registration no. UMIN000052050).
: Not applicable.
: MT reports grants from AstraZeneca KK, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan Co., Ltd., honoraria for lecture from Eli Lilly Japan Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca KK, MSD KK, Novartis Pharmaceuticals K.K, Takeda Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co.,Ltd., Daiichi Sankyo, Pfizer Japan Inc., and Janssen Pharmaceutical K.K. SM reports grants from Chugai Pharma, Janssen Pharmaceutical, MSD, Novartis, honoraria for lecture from Eli Lilly, Merck Biopharma, Chugai Pharma, Novartis pharma, Guardant Health, and AstraZeneca. KG reports all support for the present manuscript from Thermo Fisher Scientific K.K., grants from Amgen Inc., Amgen K.K., Amgen Astellas BioPharma K.K., AstraZeneca K.K., Bayer Yakuhin, Ltd., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Craif Inc., DAIICHI SANKYO Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd., Ignyta,Inc., Janssen Pharmaceutical K.K., KISSEI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., Life Technologies Japan Ltd., Loxo Oncology, Inc., LSI Medience Corporation., MEDICAL& BIOLOGICAL LABORATORIES CO., LTD., Merck Biopharma Co., Ltd., Merus N.V., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Pfizer R&D Japan G.K., Precision Medicine Asia Co., Ltd., RIKEN GENESIS CO., LTD., Sumitomo Pharma Co., Ltd., Spectrum Pharmaceuticals, Inc., Sysmex Corporation., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Turning Point Therapeutics,Inc., Xcoo, Inc., honoraria for lecture from Amgen K.K., Amoy Diagnosties Co.,Ltd., AstraZeneca K.K., Bayer U.S., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., DAIICHI SANKYO Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Guardant Health Inc., Janssen Pharmaceutical K.K., Merck Biopharma Co., Ltd., Nippon Kayaku Co.,Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., RIKEN GENESIS CO., LTD., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Thermo Fisher Scientific K.K., participation on a Data Safety Monitoring Board or Advisory Board from Amgen Inc., Amgen K.K., DAIICHI SANKYO Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd., Janssen Pharmaceutical K.K., SYNEOS HEALTH CLINICAL K.K. Other authors declare no conflicts of interest.
